Athera Biotechnologies Overview

  • Founded
  • 2002
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $5.94M
Latest Deal Amount
  • Investors
  • 6

Athera Biotechnologies General Information

Description

Operator of biopharmaceutical company intended to address the large unmet need for anti-inflammatory therapeutics in the treatment of cardiovascular disease (CVD). The company leverages technology to develop targeted anti-inflammatory biological candidate drugs for the prevention and treatment of immunovascular disease, enabling patients to reduce the risk of complications in vascular disease.

Contact Information

Website
athera.se
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Olof Palmes gata 29
  • 4th Floor
  • 111 22 Stockholm
  • Sweden
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Athera Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 21-Apr-2019 $5.94M 0000 Completed Clinical Trials - Phase 2
4. Later Stage VC 29-Aug-2017 00.000 00.000 Completed Clinical Trials - Phase 1
3. Secondary Transaction - Private 03-Dec-2015 00.000 00.000 Completed Clinical Trials - Phase 1
2. Grant 17-Jun-2013 $7.85M Completed Clinical Trials - Phase 1
1. Buyout/LBO Completed Startup
To view Athera Biotechnologies’s complete valuation and funding history, request access »

Athera Biotechnologies Patents

Athera Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2011223222-B2 Antibodies against phosphorylcholine in combination therapy with biologic agents Active 04-Mar-2010 0000000000 0
US-20160251426-A1 Antibodies against phosphorylcholine in combination therapy with biologic agents Granted 04-Mar-2010 0000000000
US-20180148502-A9 Antibodies against phosphorylcholine in combination therapy with biologic agents Granted 04-Mar-2010 0000000000
US-20130004491-A1 Antibodies against phosphorylcholine in combination therapy with biologic agents Abandoned 04-Mar-2010 0000000000 0
US-10669332-B2 Phosphorylcholine in combination therapy with infliximab Active 04-Mar-2010 C07K16/241 0
To view Athera Biotechnologies’s complete patent history, request access »

Athera Biotechnologies Executive Team (6)

Name Title Board Seat Contact Info
Anders Bergman Ph.D Chief Operating Officer & Board Member
Knut Pettersson Ph.D Chief Scientific Officer
Carina Schmidt Senior Business Advisor & Board Member
Tommy Abrahamsson Senior Advisor CVD Pharmaceuticals
James Hall Ph.D Chief Executive Officer & Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

Athera Biotechnologies Board Members (9)

Name Representing Role Since
Anders Bergman Ph.D Athera Biotechnologies Chief Operating Officer & Board Member 000 0000
Carina Schmidt Athera Biotechnologies Senior Business Advisor & Board Member 000 0000
Gunnar Olsson Ph.D Self Chairman 000 0000
James Hall Ph.D Self Chief Executive Officer & Board Member 000 0000
Johan Kordel Ph.D Industrifonden Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Athera Biotechnologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Athera Biotechnologies Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Sciety Venture Capital Minority 000 0000 000000 0
Antaros Medical Corporation Minority 000 0000 000000 0
Ribbskottet Corporation Minority 000 0000 000000 0
Industrifonden Venture Capital Minority 000 0000 000000 0
Linc (Sweden) Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »